-

Agilent Announces Inspirational LC/TQ and LC/Q-TOF Mass Spectrometry Solutions at ASMS 2023

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the high-end performance of the Revident LC/Q-TOF, Agilent is also announcing the new Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software.

The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity. The 6495 LC/TQ incorporates numerous intelligence features that address the critical transition between the ‘discovery phase’ of research and the ‘translational phase’ where studying a large volume of samples is crucial for generating meaningful scientific insights. The 6495 LC/TQ instrument was built for research with production-ready robustness, ensuring increased sample measurements due to greater efficiency and reduced instrument downtime. Intelligence features also include sub-millisecond dwell times and Intelligent Reflex that provides fast, sensitive, high-quality data, while early maintenance feedback and scheduled tuning keep the LC/TQ in peak working condition.

The Agilent Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System offers an entirely new instrument architecture coupled with instrument intelligence for maximized operation time and productivity. Revident is targeted toward food safety and environmental analysis but also has applications in other small molecule markets, from metabolomics to pharmaceuticals. Incorporating the new MassHunter Explorer Software, untargeted analyses are simplified by allowing data exploration, including statistical analysis and identification in a single software. Tasks can be performed faster with fewer errors and less expertise without compromising quality or accuracy. Additionally, the new ChemVista library manager software integrates extensive curated libraries. It enables third-party import and export into a tool that conveniently connects to MassHunter, allowing access to vast external databases for identification workflows.

“The new 6495D LC/TQ offers significant improvements in sensitivity and speed over the current 6495C, which is already a reputable high-end LC/TQ, while the Revident LC/Q-TOF is the first of a new generation of LC/Q-TOF systems,” said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions.

“This launch expands the instrument intelligence from our TQ product line to our Q-TOF. Revident also includes a novel detection system that greatly enhances spectral purity, and combined with our new MassHunter Explorer Profiling and ChemVista library manager software, the Revident LC/Q-TOF is revolutionizing our customers’ experience with LC/Q-TOF—providing the highest, yet relevant, performance for meaningful scientific insights,” Seshadri added.

Agilent is a leading solution provider of proven, robust, and reliable mass spectrometry technologies to a range of segments and a wide array of applications in the bio/pharma, life science research, food, and environmental markets. These new technological capabilities enable Agilent’s customers to increase data quality and interpretation while reducing the time and human attention required—more easily adapting to ever-changing market needs.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies, Inc.
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies, Inc.
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom